BIOTRONIK: BIO-LIBRA Initial Interim Analysis Results Demonstrate Higher Probability of Ventricular Tachyarrhythmias or Mortality in Men than Women

In conjunction with BIOTRONIK, Valentina Kutyifa, MD, PhD, presented the first interim analysis results from the BIO-LIBRA study in a poster contribution at the American College of Cardiology’s 71st Annual Scientific Session.

Women have been traditionally underrepresented in clinical trials conducted in patients with implanted medical devices, contributing to only 20-25 percent of the study population, significantly limiting our understanding of sex-specific outcomes. In a quest to close this gap, Valentina Kutyifa, MD, PhD, Jeanne Poole, MD, and BIOTRONIK designed and conducted the BIO-LIBRA study to ensure that men and women are equally represented.

The results presented today show significant differences in one-year ventricular tachyarrhythmia or death rates by sex in patients with non-ischemic cardiomyopathy with an ICD or CRT-D. The one-year probability of VT/VF or death was 7% in women and 13% in men, higher than expected by the study investigators.

View BIO-LIBRA One-Year Results Here

The BIO-LIBRA study, launched in 2019, is a multi-center, prospective, observational registry study designed to improve our understanding of outcomes in men and women with non-ischemic cardiomyopathy and an implanted ICD or CRT-D, while also observing demographic differences. The study has enrolled 1,000 patients with non-ischemic cardiomyopathy with an ICD or CRT-D at 48 centers through the United States. The primary endpoint of BIO-LIBRA is ventricular tachyarrhythmia or death.

BIO-LIBRA has been designed to specifically encourage a minimum of 40% female enrollment as a way of addressing the limited contemporary data available on sex-specific outcomes as related to this type of treatment.

The results announced today include the study’s initial 500 patients with a completed 1 year of follow-up. This population is 47% female, which exceeds stated goals, and 37% of the subjects are non-white, truly representing a diverse population more representative of the real world.

Further results will be presented as the study progresses.

BIOTRONIK notes Kutyifa V presented at ACC.22 – Poster Contribution April 4, 2022, Session 1558 – Heart Failure and Cardiomyopathies

 

SourceBIOTRONIK
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy